(Q43036832)

12 November 2017

title

Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo (English)

1 reference

12 November 2017

1 reference

1 reference

Kazuaki Inoue

1

1 reference

12 November 2017

Takuya Umehara

2

1 reference

12 November 2017

Urs T Ruegg

3

1 reference

12 November 2017

Fumihiko Yasui

4

1 reference

12 November 2017

Tsunamasa Watanabe

5

1 reference

12 November 2017

Hiroshi Yasuda

6

1 reference

12 November 2017

Jean-Maurice Dumont

7

1 reference

12 November 2017

Pietro Scalfaro

8

1 reference

12 November 2017

Makoto Yoshiba

9

1 reference

12 November 2017

Michinori Kohara

10

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

12 November 2017

1 reference

12 November 2017

volume

45

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

921-928

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

12 November 2017

cites work

1 reference

Near completely humanized liver in mice shows human-type metabolic responses to drugs

21 January 2018

1 reference

Genetic organization and diversity of the hepatitis C virus

21 January 2018

1 reference

7 January 2021

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

7 January 2021

Novel insights into hepatitis C virus replication and persistence

1 reference

7 January 2021

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

7 January 2021

Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

1 reference

7 January 2021

Interferon combined with cyclosporine treatment as an effective countermeasure against hepatitis C virus recurrence in liver transplant patients with end-stage hepatitis C virus related disease

1 reference

7 January 2021

Cyclophilin B is a functional regulator of hepatitis C virus RNA polymerase

1 reference

7 January 2021

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

1 reference

7 January 2021

The nonimmunosuppressive cyclosporin analogs NIM811 and UNIL025 display nanomolar potencies on permeability transition in brain-derived mitochondria.

1 reference

7 January 2021

Naturally occurring capsid substitutions render HIV-1 cyclophilin A independent in human cells and TRIM-cyclophilin-resistant in Owl monkey cells

1 reference

7 January 2021

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

7 January 2021

Host sphingolipid biosynthesis as a target for hepatitis C virus therapy

1 reference

7 January 2021

Intracellular-diced dsRNA has enhanced efficacy for silencing HCV RNA and overcomes variation in the viral genotype

1 reference

7 January 2021

Simple aromatics identified with a NFAT-lacZ transcription assay for the detection of immunosuppressants

1 reference

7 January 2021

Hepatitis C virus replication in mice with chimeric human livers

1 reference

7 January 2021

Activation of the CKI-CDK-Rb-E2F pathway in full genome hepatitis C virus-expressing cells

1 reference

7 January 2021

Development of a simple and highly sensitive enzyme immunoassay for hepatitis C virus core antigen.

1 reference

7 January 2021

Real-time detection system for quantification of hepatitis C virus genome

1 reference

7 January 2021

Replication of the hepatitis C virus in cell culture

1 reference

7 January 2021

Diverse Effects of Cyclosporine on Hepatitis C Virus Strain Replication

1 reference

7 January 2021

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

1 reference

7 January 2021

Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.

1 reference

7 January 2021

Identifiers

DOI

10.1002/HEP.21587

1 reference

12 November 2017

1 reference